Genomate Health Resources

Case Report: JCO Precision Oncology

Genomate Health Takes the Spotlight at PMWC 2024 in Silicon Valley

Genomate AI applied to complex HER2 positive, ER/PR positive grade III invasive carcinoma

Patient Stories

Genomate Health’s 2024 in Review

Publications

Case Report: JCO Precision Oncology

Remenár É, Dóczi R, Dirner A, Sipos A, Perjési A, Tihanyi D, Vodicska B, Lakatos D, Horváth K, Kajáry K, Schwáb R, Déri J, Lengyel CG, Várkondi E, Vályi-Nagy I, Peták I.Read Article

Case Report: MDPI NSCLC

Urbán L, Dóczi R, Vodicska B, Kormos D, Tóth L, Takács I, Várkondi E, Tihanyi D, Lakatos D, Dirner A, Vályi-Nagy I, Peták I.Read Article

Case Report: Clinical Lung Cancer Journal

‍Urbán L, Dóczi R, Vodicska B, Tihanyi D, Horváth M, Kormos D, Takács I, Pápai-Székely Z, Póka-Farkas Z, Várkondi E, Schwáb R, Hegedüs C, Vályi-Nagy I, Peták I.Read Article

Latest Events

Genomate Health Takes the Spotlight at PMWC 2024 in Silicon Valley

January 24, 2024

Silicon Valley, CA

January 24, 2024

Silicon Valley, CA

Genomate Health at the 3rd Indian Cancer Congress 2023

November 2-5, 2023

November 2-5, 2023

Patient Stories

See all

Genomate AI applied to complex HER2 positive, ER/PR positive grade III invasive carcinoma Read Article

No items found.

Latest News

Genomate Health’s 2024 in Review

Genomate Health Welcomes Thabis/Digosys as Vietnam Exclusive Distributor

Genomate Health joins the NVIDIA Inception Program

Media Coverage

How Vietnam is Leveraging AI to Reshape Healthcare

December 1, 2024

Genomate Health Welcomes Digosys (Thabis) as Vietnam Exclusive Distributor

November 4, 2024

Webinar: Matching Patients with Treatments

The Genomate® Report can be used and clinically interpreted only by physicians or other qualified healthcare professionals. Genomate® is a clinical decision support software and is not intended to diagnose, treat, cure, prevent, or mitigate any condition. None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Learn more.